1 Interleukin 21 is a marker of Human African Trypanosomiasis Infection and a

2 contributor to pathology in mice

- 3 Paul Capewell¹, Hamidou Ilboudo^{2,3,4}, Anneli Cooper¹, Windingoudi Justin Kaboré², Harry
- 4 Noyes⁵, Kerry O' Neill¹, Mamadou Camara², Vincent Jamonneau⁴, Annette MacLeod^{1§} and
- 5 Bruno Bucheton^{2,4§*} for the TrypanoGEN+ research group of the H3Africa consortium
- 6 *To whom correspondence should be addressed: Bruno BUCHETON bruno.bucheton@ird.fr

7 § joint last authors

⁸ ¹Wellcome Centre for Integrative Parasitology, College of Medical, Veterinary, and Life

- 9 Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland,
- 10 United Kingdom.
- ²Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la
 Santé, Conakry, Guinea.
- ³Institut de Recherche en Sciences de la Santé (IRSS)—Unité de Recherche Clinique de
 Nanoro (URCN), Nanoro, Burkina-Faso.
- ⁴Institut de Recherche pour le Développement, UMR INTERTRYP IRD-CIRAD, Université de
- 16 Montpellier, TA A-17/G, Campus International de Baillarguet, 34398 Montpellier, France.
- ⁵Centre for Genomic ResearchBiosciences Building,Crown Street Liverpool,United Kingdom.
- 18

19 Abstract

Background: Human African trypanosomiasis (HAT) is an important disease of sub-Saharan Africa that is approaching elimination in many regions. However, the disease has previously returned from similarly low case numbers in the past, making it important to identify issues that hinder elimination efforts. One important factor is likely to be the recent characterization of individuals with latent HAT infections that are able to tolerate HAT with few symptoms and to NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. control blood parasitaemia to levels that are undetectable by microscopy. Although animal
trypanotolerance has been examined in detail, it is unclear how the latent phenotype is
maintained in humans.

Methods: To identify immune components involved in latent HAT, we used targeted RNASeq to examine the expression of 495 immune-related transcripts in blood collected from 287 individuals at active disease foci in Guinea. These samples included latent infections, HAT clinical cases, and uninfected controls. The *in vivo* effects of IL21 functional blockade was investigated using a murine model of trypanosomiasis.

Results: Differential expression analysis revealed transcripts involved in T cell activation and B cell development that associated with trypanosome infection, including *PD1*, *CD70*, and *CD80*. In particular, *IL21* was found to be elevated in infected individuals, although it was significantly higher in clinical cases relative to latent infections. This pattern was replicated at the protein level when patient sera were examined by ELISA. Reducing IL21 pathway activity in mice infected with *Trypanosoma brucei* led to increased survivorship and reduced parasitaemia in the model animals.

40 **Conclusion:** Our data show that IL21 is a potential biomarker of Human African 41 Trypanosomiasis and is a cause rather than a consequence of symptoms severity. Further 42 investigation of IL21 will contribute to understanding the factors involved in developing latent 43 HAT, improving control efforts to identify and predict such infections. In the future, the factors 44 identified in this study may also serve as intervention targets to control the symptoms of 45 trypanosomiasis.

46 Introduction

Human African trypanosomiasis (HAT) is an important vector-borne disease of sub-Saharan
Africa primarily caused by the parasite *Trypanosoma brucei gambiense (T. b. gambiense)* [1].
The related veterinary disease animal trypanosomiasis (AT) is also a significant economic
burden involving a complex of trypanosome species, including *T. congolense, T. vivax*, and *T.*

51 b. brucei [2]. HAT has been targeted for elimination as a public health problem by 2020 by the World Health Organization (WHO) and reported cases have fallen below 1,000 in recent years 52 53 [1,3]. The next objective on the HAT control road map is to reach the interruption of transmission 54 by 2030. However, several issues have recently been identified that could hinder these efforts. 55 These include the description of individuals able to tolerate the disease with few symptoms 56 which has overturned of the long-held belief that HAT is invariably fatal. These individuals also 57 display low blood parasitemias and despite positive responses to the serological screening 58 tests, they are generally left untreated by the control programs as the microscopic confirmation 59 of trypanosomes is required in order to initiate treatment [4-8]. These latent infections are 60 initially identified by an elevated response to the card agglutination test for trypanosomiasis (CATT) and then further examined using an immune trypanolysis test targeting the LiTAT1.3 61 Variable Surface Glycoprotein known to be highly specific for T.b. gambiense in humans [9]. 62 63 These individuals, termed SERO TL+, are definitively characterised as harbouring a latent infection only if they maintain serological positivity for at least two years without developing 64 symptoms while remaining negative to parasitological tests performed on biological fluids [5,6]. 65 During a two-year longitudinal study led in Guinea, 13% of SERO TL+ individuals developed 66 67 symptoms with detectable parasites (termed SERO TL+/HAT), 48% remained latent [5] and 39% became negative to the CATT in a probable process of selfcure [5]. The latent period can 68 be extremely protracted, with one case persisting for 29 years before an unrelated 69 immunosuppressive treatment led to rapid onset of HAT [10]. It has also recently been revealed 70 that African trypanosomes are not exclusively parasites of the blood and can exists in tissues 71 72 of the host. Most notably, they can colonise the skin where they could act as a significant but 73 overlooked anatomical reservoir [11-13]. Modelling suggests it is likely that these latent 74 infections carry infective parasites and are able to maintain HAT in disease foci without animal 75 reservoirs despite intensive control efforts [14]. This is supported by xenodiagnosis experiments 76 examining asymptomatic people [15] and animals [16] demonstrating that the tsetse vector can 77 be infected by latent hosts and more recently by the detection of trypanosomes in skin biopsies 78 sampled in Guinea from both confirmed HAT patients but also serologically positive individuals

that displayed ortherwise negative parasitology in blood or lymph [17]. The genotypes of parasites from SERO TL+ individuals are indistinguishable from those infecting clinical cases [7] and genomic analyses of *T. b. gambiense* isolates from across Africa show that the parasite is clonal and highly homogenous [18]. Together, these data suggest that the host is the primary mediator of the differences in symptom severity that can lead to latent infections and SERO TL+ individuals.

Investigations of the APOL1 G1 and G2 polymporphisms within the TrypanoGEN network 85 evidenced a genetic association between the G2 polymorphism and resistance to T. b. 86 87 rhodesiense infection [19,20] as well as an increased frequency of G1 carriage in individuals with latent T. b. gambiense infections [20][21]. Several immunological studies targeted to 88 specific immune mediators have also revealed differences in the immune response between 89 SERO TL+ and HAT patients. IL8 was elevated in SERO TL+ and in these individuals was 90 91 predictive of the CATT becoming negative during the follow-up. In addition immunosuppressive molecules such as IL10 and the maternal human leukocyte antigen protein HLA-G were found 92 93 more elevated in HAT patients and SERO TL+ individuals who subsequently developed the 94 disease [22,23]. However, no causative links between immune factors and latent infections have 95 been demonstrated and the design of earlier studies to decipher the mechanisms of infection 96 resistance/susceptibility in human have had to largely rely on data from studies of 97 trypanotolerant animals. Trypanotolerance has been extensively studied in mice and cattle 98 [24,25], although the majority of such studies have used the animal trypanosome species T. 99 congolenese, T. vivax, and T. b. brucei rather than T. b. gambiense. The term trypanotolerance 100 is also somewhat misleading as these animals do become infected with trypanosomes, develop 101 adverse effects and mount an immune response. Trypanotolerance should rather be 102 understood as reduced pathology and disease in the presence of infection. Despite the different 103 parasite species used, studies of trypanotolerant animals suggest some factors that may affect 104 disease presentation in humans [26]. These include the importance of a strong IFNg-mediated response early in infection to control the initial peak of parasitaemia, followed by reduction in 105

the IFNg-mediated inflammatory environment that leads to a long-term and less virulent infection. Key to mediating this environmental shift are the cytokines IL10 and IL4. A robust B cell and humoral response is also required to control the parasite, particularly during the initial peak of parasitaemia [27].

110 To more fully understand the immune components involved in HAT symptom severity and the development of human latent infections, we compared the peripheral blood transcriptomes of 111 112 T. b. gambiense HAT clinical cases, people with latent infections and uninfected controls using a targeted immune transcript analysis. This revealed transcripts involved in T cell activation and 113 114 B cell development that differed between clinical and latent cases. More specifically, expression of the cytokine *IL21* at both the transcript and protein level associated with symptom severity. 115 116 Subsequent in vivo experiments using functional blockade confirmed that IL21 is involved in 117 determining both symptom severity and parasitaemia during trypanosome infection. This 118 cytokine therefore serves as both a biomarker of trypanosome infection and also offers a new intervention target to limit symptoms of the disease in humans and animals. 119

120 Methods

121 Study Design

122 Participants were identified during medical surveys organised by the Guinean National Control Programme (NCP) of HAT from three HAT foci in Guinea (Dubreka, Boffa, and Forecariah) 123 124 according to the WHO and NCP policies [5,28]. Five mL samples of blood were collected in 125 heparinised tubes from individuals who tested positive for infection using the card agglutination 126 trypanosomiasis test (CATT). A 2-fold dilution series of patient blood was tested to estimate CATT titre. Individuals with titres 1/4 or greater were submitted for microscopic examination of 127 128 lymph node aspirates and 350 µl of buffy coat were examined for the presence of trypanosomes using mini-anion exchange centrifugation test (mAECT). If trypanosomes were detected, lumbar 129 puncture was performed, and disease stage determined by identifying trypanosomes and by 130 white blood cell (WBC) counts. Confirmed HAT cases were classified as stage 1 (0–5 WBC/µL), 131

132 early stage 2 (6–20 WBC/µL; or ≤20 WBC with trypanosomes in CSF), or late stage 2 (>20 WBC/µL) and treated according to NCP guidelines [28]. For each study individual, 100 µL of 133 plasma was sampled and 2 mL of blood were taken on PAXgene[®] Blood RNA tubes 134 (PreAnalytiX). All samples were frozen in the field at -20°C in car freezer and were then stored 135 at -80 °C until use. The plasma was used to perform the immune trypanolysis test to detect Litat 136 1.3 and Litat 1.5 variable surface antigens specific for *T. b. gambiense* [9]. The PAXgene® blood 137 RNA tubes were used to extract RNA with PAXgene® Blood RNA kit (PreAnalytiX). CATT and 138 139 trypanolysis positive subjects without visible parasites were defined as SERO TL+. SERO TL+ individuals were followed-up for at least two years (with an average of three visits) and of these, 140 11 went on to develop HAT and were defined as SERO TL+/HAT. Those that remained CATT 141 142 and trypanolysis positive for at least two years were defined as having latent infections.

143 Targeted RNASeq

144 A Qiagen Human Inflammation & Immunity Transcriptome Kit (RHS-005Z; Qiagen) was used to 145 obtain transcript counts from a panel of 495 genes involved in the innate and acquired immune responses (Supplementary File 1). cDNA libraries were prepared from 56 uninfected controls, 146 147 168 HAT cases (135 pre- and 33 post-treatment). 36 SERO TL+ samples with latent infections 148 and 11 individuals who were intitially CATT and TL positive but parasitologically negative but 149 became parasitologically positive on follow up (SERO/HAT). The resulting Illumina libraries 150 were sequenced on an Illumina NextSeg 500 and filtered and mapped using Qiagen GeneGlobe 151 software (Qiagen). Normalization and pairwise differential expression analysis for each 152 transcript were performed by Qiagen using DESeq2 for R [29] and normalised read counts are 153 provided as Supplementary Data File 4.

154 IL21 ELISA

A human IL21 ELISA kit (ab119542; Abcam) was used to measure IL21 titres in sera from eight
samples randomly selected from each group (Control, HAT, SERO TL+, and SERO/HAT)
following the manufacturer's instructions. There were three replicates for each sample.

158 Anti-IL21 intervention

To assess the effects of reducing IL21 pathway function in vivo, 8-week-old female BALB/c mice 159 were housed in a specific pathogen-free environment in accordance with local and Home Office 160 regulations. Two experiments were performed using four mice treated with 100 µg recombinant 161 162 anti-IL21 neutralizing antibody every other day from day -1 (FFA21; Thermo Fisher Scientific). These concentrations were selected based on previous in vivo studies examining the role of 163 IL21 during viral infection [30]. In addition, four mice per experiment were injected with 100 µg 164 isotype antibody on the same days to serve as controls (Rat IgG2a κ ; Thermo Fisher Scientific). 165 166 All mice were inoculated intraperitoneally with 10⁴ STIB247 T. b. brucei parasites on day 0 and parasitaemia was assayed on each subsequent day using phase microscopy [31]. 167

168

169 **Results**

170 Targeted RNASeq

In order to identify potential differentiators between infected individuals (both SERO TL+ and 171 HAT) and controls, in addition to clinical cases and latent individuals, a cost-effective targeted 172 RNASeg approach was used to examine 495 immune-related genes in whole blood RNA 173 174 purified from 271 individuals from active disease foci in Guinea. The targeted genes encompass various canonical B cell and T cell pathways (Supplementary File 1). The sample library 175 176 included uninfected controls (n = 56); HAT cases pre-treatment (n = 135); post-treatment HAT cases (n = 33); latent infections (SERO TL+ individuals who had remained serology positive 177 and parasitologically negative for two years) (n = 36) and SERO/HAT (individuals who were 178 179 seropositive but parasitiologically negative at first screening but became parasitologically positive at a later screening) (n = 11). Normalised read counts for all genes and participants are 180 available in Supplementary data file 4. The expression profiles of these groups were then 181 compared pairwise to reveal differentially expressed transcripts (Supplementary 3; Figure 1). In 182 a comparison of HAT cases versus controls, 10 transcripts were found to be differentially 183

184 regulated with an FDR p adj < 0.001 (Figure 1A). Expression of the high affinity IgE receptor FCER1A was lower in HAT cases, but the expression levels of IL21, CD1C, TLR10, IL12B, PD1, 185 186 CD70, CD80, CAV1, and MET were all higher. No significant differences were found between 187 HAT cases post-treatment and controls, although a comparison of HAT cases pre- and post-188 treatment revealed that the expression levels of IL21, CD1C, IL10, IL12B, CAV1, and MET were 189 all significantly higher in the pre-treatment group (p adj < 0.001; Figure 1B). A comparison of 190 individuals with latent infections versus controls found only two transcripts that differed 191 significantly in expression (*IL21* and *IL12B*) with $p_adj < 0.001$ (Figure 1C). Both of these 192 transcripts were also significant in the HAT versus control comparison. Finally, a comparison of 193 individuals with latent infections and HAT clinical cases found four transcripts that showed 194 significant differences in expression (CD1C, IL21, CAV1, and MET) with $p_{adj} < 0.001$ (Figure 195 1D). Again, these transcripts were significant in the HAT clinical cases versus control 196 comparison. It was noted that IL21 was significant across multiple comparisons and elevated in both HAT and latent infection groups. However, expression was significantly higher in the 197 198 clinical HAT group relative to the latent infection cohort, suggesting it may be involved in the 199 development of HAT symptoms. To establish if the pattern observed in IL21 transcript 200 expression correlated with the protein level, an anti-IL21 ELISA was performed using sera from a subset of samples from each group (n = 8 for each group). This confirmed that the pattern of 201 IL21 expression at the protein level was the same as the transcript level, being elevated in 202 infected individuals but much higher in clinical HAT (Figure 2). Finally, to assess if IL21 levels 203 may be predictive for SERO TL+ individuals that go on to develop HAT, titres from the 11 204 SERO/HAT individuals were also examined. These samples were taken from patients that were 205 206 serologically positive without symptoms but went on to develop disease with detectable parasitaemia during the two-year follow-up period. This differs from the SERO TL+ group that 207 208 maintained their latent phenotype with undetectable parasitaemia. IL21 titres in the SERO/HAT 209 group that progressed to active disease were not found to be significantly different from SERO 210 TL+ individuals that maintained their latent phenotype for the duration of the study, suggesting 211 that elevated IL21 is associated with infection rather than acting as a predictive marker of risk

- of developing active disease. Nevertheless, these data reveal that *IL21* transcript and IL21
- 213 protein are elevated during trypanosome infection and are higher in clinical HAT cases relative



to latent SERO TL+ infections.

216 Figure 1. Genes with differential expression between latent infections, HAT, and Control groups. Volcano plots demonstrating the relationships between $-\log_{10}(p_{adj})$ values) and the 217 log₂ fold change values obtained from DESeq2. Genes showing differential expression with a 218 219 p_{adj} value above 0.05 and log_2 fold change \leq -1 or \geq 1 are coloured red (up-regulated) or blue (down-regulated). The panels show significant genes identified in comparisons between (A) 220 221 clinical HAT cases versus controls, (B) clinical HAT cases versus HAT post-treatment, (C) individuals with latent infections versus controls, and (D) individuals with latent infections versus 222 HAT cases. 223



224

225

226 Figure 2. Serum IL21 Titres and mRNA expression show that both protein and mRNA levels increase after infection . (A) IL21 titres were assessed by ELISA for a random subset 227 of control, latent infections (SERO TL+), individuals with HAT and those who have developed 228 active HAT after first presenting with just positive serology (SERO/HAT). Sera were from the 229 targeted RNASeq study (n = 8 per group). There was a significant difference between both 230 SERO TL+ and SERO/HAT individuals and HAT patients (T-Test, p < 0.01) but no difference 231 between SERO TL+ and SERO/HAT individuals (T test, p = 0.90). (B) IL21 mRNA from the 232 targeted RNAseq data representing the same groups. 233

234 IL21 Functional Intervention

235 To establish whether IL21 was a cause or consequence of HAT severity, the IL21 pathway was inhibited using a neutralising anti-IL21 antibody in a HAT mouse model across two trials 236 (parasitaemia data are presented in Supplementary File 2). During the first trial, one animal in 237 the control group treated with isotype control succumbed to trypanosomiasis at day eight and 238 the remaining controls were euthanized due to severe illness. All of the mice in the experimental 239 group treated with the neutralising antibody were healthy and presented with no symptoms, 240 although they were also euthanized due to the terms of the license under which the work was 241 performed. During the second trial, the experiment was again curtailed at day eight due to 242 severe symptom and paralysis in the control group. As in the previous experiment all of the mice 243

244 treated with anti-IL21 antibody were visibly healthy. This suggests that the IL21 pathway is involved in increased symptom severity during trypanosome infection rather than being simply 245 a consequence of symptom development. However, the early end of these experiment means 246 further work is required to fully understand the mechanisms involved. In addition, when the 247 248 parasitaemia curves from the two independent experiments were aligned to the first peak of 249 parasitaemia, a significant interaction effect was observed between treatment and day (ANOVA, 250 F = 3.02, p < 0.01). An interaction effect represents the combined effects of factors on the 251 dependent measure (parasitaemia), with the impact of one factor depending on the level of 252 another factor. In this case, the effect of the neutralising anti-IL21 antibody on parasitaemia 253 depended on days post-infection (Figure 3). When days were examined individually, there was a significant difference observed in the magnitude of the first peak of parasitaemia between 254 treated and control groups (T Test, p = 0.03). These data show that administration of the anti-255 256 IL21 antibody affected parasite number in addition to affecting symptoms, demonstrating that IL21 has a significant impact on parasitaemia and symptom severity during African trypanosome 257 infections. In particular, reducing IL21 pathway function associates with better outcomes and 258 lower parasitaemia. 259



261 Figure 3. The effect of IL21 functional blockade on parasitaemia in a HAT model. Eight mice were infected with T. b. brucei STIB247 across two different experiments. Mice were 262 administered with a blocking anti-IL21 chimera antibody (red line) or an isotype control (blue 263 line) on alternate days beginning the day before inoculation. Parasitaemia was estimated daily 264 265 via microscopy and the resulting curves were aligned to the first peak (day 0) to account for individual variation. Blocking IL21 consistently reduced parasitiaemia. Mean parasitaemia for 266 267 treatment and isotype control are shown with 95% confidence intervals. A significant interaction 268 effect was observed between treatment and days post-infection (ANOVA, p < 0.01) and there 269 was a significant difference observed in size of the first parasitaemia peak (T Test, p = 0.03).

270

271 Discussion

272 As HAT approaches elimination, it becomes increasingly important to identify and understand factors that may impact the control of this deadly parasite, particularly latent infections, and the 273 274 role of the skin as an anatomical reservoir [3,32]. Our study used RNASeq on a panel of 496 275 genes involved in the innate and acquired immune responses to identify immune components involved in the latent phenotype in 260 individuals from HAT active foci in Guinea. When 276 277 comparing HAT cases and controls, we identified 10 transcripts that associate with clinical 278 disease, some of which have never previously been identified as being involved in HAT. These 279 included transcripts for IL21, IL12B, IL10, CD1C, TLR10, PD1, CD70, CD80, CAV1, and MET. Interleukin-12 subunit beta (IL12B) is a component of IL12, a cytokine involved in a wide range 280 281 of immune responses during infectious challenge [33,34]. However, the subunit is also a 282 component of IL23, and our data is unable to assign this increase in IL12B expression to IL12, 283 IL23, or both. However, IL23 is an important mediator of Th17-mediated and GM-CSF responses involved in controlling extracellular parasites [35]. Many of the protective roles 284 assigned to IL12 are now also being reassessed in light of the description of IL23 [36]. Further 285 work is therefore required to establish whether IL23 expression is important during African 286 trypanosome infection and to establish the role of Th17 responses. Transcripts involved in T 287

288 cell activation and exhaustion were also identified, including PD1 and CD70 (both immune checkpoint markers), and CD80 (a receptor for the co-stimulatory protein CD28). The 289 involvement of T cell activation and co-stimulation imply that increased T cell activation is 290 occurring in infected individuals, likely in response to the presence of a pathogen. However, it 291 292 has also been suggested that African trypanosomes possess a lymphocyte triggering factor (TLTF) that drives polyclonal (non-specific) T activation [37,38], leading to higher expression of 293 294 proteins associating with immune exhaustion and suppression. PD1, highlighted in our study, is 295 one such suppressive protein that acts via its ligands (PDL1 and PDL2) to down-regulate the 296 immune system and promote self-tolerance [39]. Although PD1 has not previously been 297 associated with trypanosome infection, the pathway has been implicated in the response and 298 control of several important parasites, including Toxoplasma, Leishmania, and Plasmodium 299 [40-42]. Both PD1 and IL10 were elevated in HAT cases and they co-operate to suppress CD8+ 300 Tcells [43]. Severe immune suppression is a classically described feature of African 301 trypanosome infection in humans and livestock [44][45] and we hypothesize that this may be 302 due to increased activation of IL10 and the PD1 pathway in infected hosts. Further investigation 303 is required to establish if this is the case and whether intervention can alleviate immune 304 suppression and improve symptoms, as shown for Plasmodium [41] and Leishmania donovani 305 [42].

306 Very little is known about Toll-like receptor 10 (TLR10) as mice do not possess the protein, 307 limiting investigation [46]. However, unlike all other TLRs, it is immune suppressive and may 308 therefore be involved in the systemic immune suppression seen during trypanosome infections 309 [47]. Our data indicate that African trypanosomes may serve as a powerful model system to 310 elucidate some of the mechanisms of these understudied immune proteins. Finally, our 311 comparison between HAT cases and controls revealed that the high affinity IgE receptor 312 FCER1A showed lower expression in infected patients. Previously it has been shown in trypanosome-infected rats that there is a reduced anaphylaxis due to parasite-mediated 313 disruption of IgE-specific pathways [48]. Our data suggest a similar effect may occur in humans 314

315 and that lowered expression of FCER1A may contribute to a decrease in IgE responses. It is unclear why African trypanosomes would target these anaphylactic pathways, but it may be 316 317 related to controlling the immune response in the skin. Previous data has shown that there is 318 almost no inflammatory reaction to trypanosomes present in the skin of infected mice, despite 319 high parasite burdens [12]. Finally, our data show that after treatment, the expression of these 320 transcripts, including immune suppressive transcripts such as PD1, return to levels equivalent 321 to controls. This suggests that the perturbation to a patient's immune system is not permanent. 322 A similar effect has been observed in the immune systems of HAT patients that have been 323 previously examined [49].

324 Across each of the targeted RNASeg comparisons, *IL21* has emerged as a recurring factor that was highlighted as elevated in both HAT cases and latent infections versus controls. However, 325 326 *IL21* transcript levels were lower in latent cases when compared to HAT patients. This suggests 327 that *IL21* is elevated during trypanosome infection but is significantly higher in clinical cases. This pattern was confirmed at the protein level by ELISA. Our subsequent in vivo intervention 328 329 using a mouse model of HAT has confirmed that reducing the activity of the IL21 pathway 330 through functional blockade leads to higher survival rates and reduced parasitaemia in infected 331 animals. This demonstrates that *IL21* expression influences the severity of symptoms rather 332 than elevated expression simply being a consequence of African trypanosome infection. In 333 contrast blockade of IL21 or IL21R in mice infected with Plasmodium chabaudi lead to sustained 334 high parasitaemia and a failure to resolve the chronic stage of the infection [50]. IL21 is a 335 pleiotropic cytokine with a wide range of interactions across immune and non-immune cell types 336 [51]. It is primarily made by activated T cells, particularly T follicular helper (Tfh cells), and one 337 of its primary functions is to promote B cell development and maintain humoral responses [52]. 338 Patients with defective IL21 signalling are severely immune compromised, suffering from 339 deficiencies in plasma cell and memory B cell generation, as well as immunoglobulin class 340 switching [53-55]. They also suffer from repeated secondary infections due to increased susceptibility to infection [54]. However, IL21 has been described as a "double-edged sword" 341

342 due to a complicated role in immunity, either supporting and suppressing B cell development depending on serum levels and interactions with other cytokines present [51][56]. In particular, 343 344 IL21 has a potent immunosuppressive effect at high serum titres, primarily through Tfh driving cell cycle arrest and apoptosis in B cells [57-59]. Interestingly, destruction of the B cell 345 346 compartment is a distinctive component of African trypanosome infection in mice [60], although this effect may be less pronounced during more chronic T. b. gambiense infections [61]. 347 348 Nevertheless, our data suggest that disruption of the B cell population in mice may be due to 349 elevated IL21 levels and further experimentation is required to confirm this hypothesis. Although 350 we did not observe a decrease in B cell numbers during our in vivo experiments (data not 351 shown), these data were collected on day eight and B cell destruction was not noticeable until 352 after day 10 in previous studies [60].

Based on our data, we hypothesize that a perturbation in T cell activation and B cell 353 354 development contributes to immune suppression, higher parasitaemia, and the development of 355 symptoms in clinical HAT cases. IL21 appears intimately involved in these affects and our data 356 suggest that latent infections with reduced symptoms are in some part due to the control of this 357 cytokine. As IL21 is primarily produced by activated T cells, reducing activation would lead to 358 less activity in the IL21 pathway, maintaining a robust B cell and humoral response. In a previous 359 study that examined trypanosome-mediated polyclonal T cell activation in susceptible and 360 resistance mice, more resistant strains differed in their response to the polyclonal activator TLTF 361 by increasing expression of cytokines associated with antibody synthesis and class switching 362 [62]. While this supports our hypothesis, much more investigation is required to establish which cell populations are expressing IL21 and whether blockade of activation checkpoint proteins 363 (such as PD1) can alleviate symptoms in an animal model of HAT. In *Plasmodium* infections, 364 365 polyclonal T cell activation caused by the parasite leads to elevated expression of PD1 on Tfh 366 cells, again leading to impaired B cell and humoral responses. When PD1-mediated suppression is alleviated via blocking antibodies (alongside blockade of another checkpoint 367 marker LAG3), Tfh function and B cell responses are restored, resulting in less severe 368

symptoms [41]. It is possible that a similar effect is occurring during HAT, with individuals with latent infections displaying less activation and exhaustion in the Tfh population, maintaining B cell and humoral responses, leading to a long term control of parasitaeimia but not parasite elimination. This would suggest that IL21 and PD1 are potential intervention targets that may play a role in controlling symptoms by maintaining the strength of the host immune system, particularly in livestock where the elimination of trypanosomiasis is unlikely if not impossible.

375 In addition, of its potential functional role in mediating T. b. gambiense infection outcomes, IL21 376 also appears as an interesting biomarker of trypanosome infection in human. With the upcoming 377 availability of new oral drugs, in particular Acoziborol given as a single dose, the treatment of individuals testing positive to the actual serological tests (CATT or RDTs) is likely to become a 378 reality in the coming years if the drug is proved to be safe enough [63,64]. A major challenge of 379 380 this largely simplified test and treat strategy reside in the fact that all the actual antibody 381 detection tests for HAT lack specificity and in low endemic prevalence contexts display poor positive predictive values [65]. Detection of IL21 in a simple test format in those serological 382 383 suspects is likely to enhance the identification of individuals with active infections thus reducing 384 considerably the number of "unnecessary" treatments. The fact that the plasma levels of IL21 385 were shown to be significantly higher in both latent and HAT patients as compared to controls 386 is a proof of concept that it is a reachable goal. Larger multi-centric studies integrating other co-387 infections as potential confounding factors will be required to further validate IL21 as a 388 biomarker T. b. gambiense infection in humans.

389 Conclusion

Our study is an example of successfully applying targeted transcriptomics to identify genes associating with latent carriage of HAT, highlighting IL21 as a potential biomarker of infection as well as a key mediator of symptom severity and a likely contributor to the development of a latent phenotype. Importantly, we have used an animal model to confirm the relevance of IL21 during African trypanosome infections. Further investigation of IL21, and its role in disease, will improve our understanding of the factors involved in developing clinical HAT or latent infections,

but may also contribute to the development of more productive and trypanosome tolerantlivestock breeds.

398 **Declarations**

399 Ethics approval and consent to participate

400 All investigations on humans were conducted in accordance with the Declaration of Helsinki. 401 Participants were identified through healthcare providers, community engagement and active 402 surveillance campaigns led by the national contral program, Ministry of Health Guinea. Written 403 informed consents for sample collection, analysis and publication of anonymised data was 404 obtained from all participants by trained local healthcare workers. Subjects or their legal 405 guardian gave consent as a signature or a thumbprint after receiving standardized information in French or their local langage as preferred. Ethical approvals for the study was obtained from 406 within the TrypanoGEN Project following H3Africa Consortium guidelines for informed consent 407 408 [66] and from Comité Consultatif de Déontologie et d'éthique (CCDE) at the Institut de recherché pour le Développent (IRD; 10/06/2013). Research procedures were also approved by the 409 University of Glasgow MVLS Ethics Committee for Non-Clinical Research Involving Human 410 Subjects (Reference no. 200120043). 411

All animal experiments were approved by the University of Glasgow Ethical Review Committee and performed in accordance with the UK Home Office guidelines, UK Animals (Scientific Procedures) Act, 1986 and EU directive 2010/63/EU. All experiments were conducted under SAPO regulations and UK Home Office project licence number PC8C3B25C to Dr. Jean Rodgers.

417 Competing interests

418 The authors declare that they have no competing interests

419 Funding

420 PC, AC, AML were funded by a Wellcome Senior Fellowship to AML (209511/Z/17/Z). BB was

421 funded by IRD. WJK, HN and HI, were supported through the Human Hereditary and Health in

- 422 Africa (H3Africa) [H3A/18/004]. The second phase of the Wellcome component of H3Africais
- 423 being implemented by the African Academy of Sciences (AAS) and the NEPAD Agency's
- 424 Alliance for Accelerating Excellence in Science in Africa (AESA) in partnership with Wellcome.

425 Authors' contributions

- 426 PC conducted in vitro and vivo experiments drafted manuscript; AC conducted in vitro and in
- 427 vivo experiments; WJK Sample Collection and RNA prep revised manuscript; HI Sample
- 428 Collection and RNA prep; HN Revised manuscript; KO'N In vivo experiments; MC, VJ
- 429 Managed and participated in sample collection; AM and BB Devised experiment and revised
- 430 manuscript.

431 Acknowledgements

- 432 The authors would like to acknowledge the study participants who donated their specimens,
- the personnel involved in the community engagement and coordinating sample collection and
- 434 processing, the national sleeping sickness control programmes of the participating countries.
- 435 The views expressed in this publication are those of the author(s) and not necessarily those of
- 436 AAS, the NEPAD Agency nor Wellcome.
- 437

438 **References**

- WHO. Trypanosomiasis, human African (sleeping sickness). 2020 [cited 20 Apr 2022] p. WHO
 Fact Sheet, No. 259. Available: https://www.who.int/news-room/fact sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)
- Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, De Leeuw PN. Measuring the costs of
 African animal trypanosomosis, the potential benefits of control and returns to research.
 Agricultural Systems. 1999;59: 79–98. doi:10.1016/S0308-521X(98)00086-9
- Akazue PI, Ebiloma GU, Ajibola O, Isaac C, Onyekwelu K, Ezeh CO, et al. Sustainable Elimination
 (Zero Cases) of Sleeping Sickness: How Far Are We from Achieving This Goal? Pathogens 2019,
 Vol 8, Page 135. 2019;8: 135. doi:10.3390/PATHOGENS8030135

- Ilboudo H, Bras-Goncalves R, Camara M, Flori L, Camara O, Sakande H, et al. Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFalpha are associated with subsequent disease development. PLoS Pathog. 2014;10: e1004469. doi:10.1371/journal.ppat.1004469
- Ilboudo H, Jamonneau V, Camara M, Camara O, Dama E, Léno M, et al. Diversity of response to
 Trypanosoma brucei gambiense infections in the Forecariah mangrove focus (Guinea):
 Perspectives for a better control of sleeping sickness. Microbes and Infection. 2011.
 doi:10.1016/j.micinf.2011.05.007
- 456 6. Jamonneau V, Ilboudo H, Kaboré J, Kaba D, Koffi M, Solano P, et al. Untreated Human Infections
 457 by Trypanosoma brucei gambiense are Not 100% Fatal. PLoS Negl Trop Dis. 2012.
 458 doi:10.1371/journal.pntd.0001691
- Kabore J, Koffi M, Bucheton B, MacLeod A, Duffy C, Ilboudo H, et al. First evidence that parasite
 infecting apparent aparasitemic serological suspects in human African trypanosomiasis are
 Trypanosoma brucei gambiense and are similar to those found in patients. Infect Genet Evol.
 2011;11: 1250–1255. doi:10.1016/j.meegid.2011.04.014
- Koffi M, Solano P, Denizot M, Courtin D, Garcia A, Lejon V, et al. Aparasitemic serological
 suspects in Trypanosoma brucei gambiense human African trypanosomiasis: a potential human
 reservoir of parasites? Acta Trop. 2006;98: 183–188. doi:10.1016/j.actatropica.2006.04.001
- Jamonneau V, Bucheton B, Kaboré J, Ilboudo H, Camara O, Courtin F, et al. Revisiting the immune
 trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in
 West Africa. PLoS Neglected Tropical Diseases. 2010. doi:10.1371/journal.pntd.0000917
- Sudarshi D, Lawrence S, Pickrell WO, Eligar V, Walters R, Quaderi S, et al. Human African
 Trypanosomiasis Presenting at Least 29 Years after Infection—What Can This Teach Us about the
 Pathogenesis and Control of This Neglected Tropical Disease? PLOS Neglected Tropical Diseases.
 2014;8: e3349. doi:10.1371/JOURNAL.PNTD.0003349
- 473 11. Caljon G, Van Reet N, De Trez C, Vermeersch M, Pérez-Morga D, Van Den Abbeele J. The Dermis
 474 as a Delivery Site of Trypanosoma brucei for Tsetse Flies. PLOS Pathogens. 2016;12: e1005744.
 475 doi:10.1371/JOURNAL.PPAT.1005744
- Capewell P, Cren-Travaille C, Marchesi F, Johnston P, Clucas C, Benson RA, et al. The skin is a
 significant but overlooked anatomical reservoir for vector-borne African trypanosomes. eLife.
 2016;5. doi:10.7554/eLife.17716
- Trindade S, Rijo-Ferreira F, Carvalho T, Pinto-Neves D, Guegan F, Aresta-Branco F, et al.
 Trypanosoma brucei Parasites Occupy and Functionally Adapt to the Adipose Tissue in Mice. Cell
 host & microbe. 2016;19: 837–848. doi:10.1016/J.CHOM.2016.05.002
- 482 14. Capewell P, Atkins K, Weir W, Jamonneau V, Camara M, Clucas C, et al. Resolving the apparent 483 transmission paradox of African sleeping sickness. PLOS Biology. 2019;17: e3000105.
 484 doi:10.1371/JOURNAL.PBIO.3000105
- 485 15. Frezil JL. Application of xenodiagnosis for the demonstration of T. gambiense trypanosomiasis in
 486 immunologically suspect individuals. In: Bulletin de la Société de Pathologie Exotique [Internet].
 487 1971 [cited 20 Apr 2022] p. 64: 871-878. Available:
- 488 https://www.cabdirect.org/cabdirect/abstract/19732900264

- 489 16. Wombou Toukam CM, Solano P, Bengaly Z, Jamonneau V, Bucheton B. Experimental evaluation
 490 of xenodiagnosis to detect trypanosomes at low parasitaemia levels in infected hosts. Parasite
 491 (Paris, France). 2011;18: 295–302. doi:10.1051/PARASITE/2011184295
- 492 17. Camara M, Soumah AM, Ilboudo H, Travaillé C, Clucas C, Cooper A, et al. Extravascular Dermal
 493 Trypanosomes in Suspected and Confirmed Cases of gambiense Human African Trypanosomiasis.
 494 Clinical Infectious Diseases. 2021;73: 12–20. doi:10.1093/cid/ciaa897
- 495 18. Weir W, Capewell P, Foth B, Clucas C, Pountain A, Steketee P, et al. Population genomics reveals
 496 the origin and asexual evolution of human infective trypanosomes. eLife. 2016;5.
 497 doi:10.7554/ELIFE.11473
- Kamoto K, Noyes H, Nambala P, Senga E, Musaya J, Kumwenda B, et al. Association of APOL1
 renal disease risk alleles with Trypanosoma brucei rhodesiense infection outcomes in the
 northern part of Malawi. PLOS Neglected Tropical Diseases. 2019;13: e0007603.
 doi:10.1371/journal.pntd.0007603
- 20. Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, et al. APOL1 renal risk variants have
 contrasting resistance and susceptibility associations with African trypanosomiasis. Tishkoff S,
 editor. eLife. 2017;6: e25461. doi:10.7554/eLife.25461
- 505 21. Kaboré JW, Ilboudo H, Noyes H, Camara O, Kaboré J, Camara M, et al. Candidate gene
 506 polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea.
 507 PLOS Neglected Tropical Diseases. 2017;11: e0005833. doi:10.1371/journal.pntd.0005833
- S08 22. Courtin D, Milet J, Sabbagh A, Massaro JD, Castelli EC, Jamonneau V, et al. HLA-G 3' UTR-2
 S09 haplotype is associated with Human African trypanosomiasis susceptibility. Infection, Genetics
 S10 and Evolution. 2013. doi:10.1016/j.meegid.2013.03.004
- 511 23. Gineau L, Courtin D, Camara M, Ilboudo H, Jamonneau V, Dias FC, et al. Human Leukocyte
 512 Antigen-G: A Promising Prognostic Marker of Disease Progression to Improve the Control of
 513 Human African Trypanosomiasis. Clinical Infectious Diseases. 2016. doi:10.1093/cid/ciw505
- 51424.Courtin D, Berthier D, Thevenon S, Dayo GK, Garcia A, Bucheton B. Host genetics in African515trypanosomiasis. Infect Genet Evol. 2008;8: 229–238. doi:10.1016/j.meegid.2008.02.007
- 516 25. Kemp SJ, Darvasi A, Soller M, Teale AJ. Genetic control of resistance to trypanosomiasis.
 517 Veterinary immunology and immunopathology. 1996;54: 239–243. doi:10.1016/S0165518 2427(96)05692-9
- 519 26. Mansfield JM, Paulnock DM. Regulation of innate and acquired immunity in African
 520 trypanosomiasis. Parasite immunology. 2005;27: 361–371. doi:10.1111/J.1365521 3024.2005.00791.X
- Magez S, Schwegmann A, Atkinson R, Claes F, Drennan M, De Baetselier P, et al. The role of B cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei infected mice. PLoS pathogens. 2008;4. doi:10.1371/JOURNAL.PPAT.1000122
- 525 28. Camara M, Kaba D, KagbaDouno M, Sanon JR, Ouendeno FF, Solano P. [Human African
 526 trypanosomiasis in the mangrove forest in Guinea: epidemiological and clinical features in two
 527 adjacent outbreak areas]. Med Trop (Mars). 2005;65: 155–161.

- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
 data with DESeq2. Genome Biology. 2014;15: 550. doi:10.1186/s13059-014-0550-8
- Shen Z, Yang H, Yang S, Wang W, Cui X, Zhou X, et al. Hepatitis B virus persistence in mice reveals
 IL-21 and IL-33 as regulators of viral clearance. Nature communications. 2017;8.
 doi:10.1038/S41467-017-02304-7
- Herbert WJ, Lumsden WHR. Trypanosoma brucei: a rapid "matching" method for estimating the
 host's parasitemia. Experimental parasitology. 1976;40: 427–431. doi:10.1016/00144894(76)90110-7
- Berthier D, Brenière SF, Bras-Gonçalves R, Lemesre JL, Jamonneau V, Solano P, et al. Tolerance to
 Trypanosomatids: A Threat, or a Key for Disease Elimination? Trends in parasitology. 2016;32:
 157–168. doi:10.1016/J.PT.2015.11.001
- 539 33. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human
 540 disease. Cytokine & growth factor reviews. 2000;11: 321–333. doi:10.1016/S1359541 6101(00)00010-1
- 542 34. Locksley RM. Interleukin 12 in host defense against microbial pathogens. Proceedings of the
 543 National Academy of Sciences of the United States of America. 1993;90: 5879–5880.
 544 doi:10.1073/PNAS.90.13.5879
- 54535.Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory546diseases. Immunology. 2012;135: 112–124. doi:10.1111/J.1365-2567.2011.03522.X
- S47 36. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than
 interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature.
 2003;421: 744–748. doi:10.1038/NATURE01355
- 37. Abdulla MH, Bakhiet M, Lejon V, Andersson J, McKerrow J, Al-Obeed O, et al. TLTF in
 cerebrospinal fluid for detection and staging of T. b. gambiense infection. PloS one. 2013;8.
 doi:10.1371/JOURNAL.PONE.0079281
- 38. BAKHIET M, OLSSON T, EDLUND C, HÖJEBERG B, HOLMBERG K, LORENTZHN J, et al. A
 Trypanosoma brucei brucei-derived factor that triggers CD8+ lymphocytes to interferon-gamma
 secretion: purification, characterization and protective effects in vivo by treatment with a
 monoclonal antibody against the factor. Scandinavian journal of immunology. 1993;37: 165–178.
 doi:10.1111/J.1365-3083.1993.TB01753.X
- 55839.Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity.559Immunological reviews. 2010;236: 219–242. doi:10.1111/J.1600-065X.2010.00923.X
- 40. Bhadra R, Gigley JP, Weiss LM, Khan IA. Control of Toxoplasma reactivation by rescue of
 dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proceedings of the National
 Academy of Sciences of the United States of America. 2011;108: 9196–9201.
 doi:10.1073/PNAS.1015298108
- 41. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, et al. Therapeutic blockade of
 PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nature
 immunology. 2011;13: 188–195. doi:10.1038/NI.2180

- Habib S, El Andaloussi A, Elmasry K, Handoussa A, Azab M, Elsawey A, et al. PDL-1 Blockade
 Prevents T Cell Exhaustion, Inhibits Autophagy, and Promotes Clearance of Leishmania donovani.
 Infection and immunity. 2018;86. doi:10.1128/IAI.00019-18
- Sun Z, Fourcade J, Pagliano O, Chauvin J-M, Sander C, Kirkwood JM, et al. IL10 and PD-1
 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Research. 2015;75: 1635–
 1644. doi:10.1158/0008-5472.CAN-14-3016
- 44. Roelants GE, Pinder M. Immunobiology of African trypanosomiasis. Contemporary topics in
 immunobiology. 1984;12: 225–274. doi:10.1007/978-1-4684-4571-8_7
- 45. Marañón C. Whole genome transcriptome reveals metabolic and immune susceptibility factors
 576 for Trypanosoma congolense infection in West-African livestock. PCI Infections. 2023; 100008.
 577 doi:10.24072/pci.infections.100008
- 578 46. Chuang TH, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially
 579 expressed in immune cells. Biochimica et biophysica acta. 2001;1518: 157–161.
 580 doi:10.1016/S0167-4781(00)00289-X
- 47. Hess NJ, Jiang S, Li X, Guan Y, Tapping RI. TLR10 Is a B Cell Intrinsic Suppressor of Adaptive
 Immune Responses. Journal of immunology (Baltimore, Md : 1950). 2017;198: 699–707.
 doi:10.4049/JIMMUNOL.1601335
- 48. Gould SS, Castro GA. Suppression by Trypanosoma brucei of anaphylaxis-mediated ion transport
 in the small intestine of rats. Immunology. 1994/03/01 ed. 1994;81: 468.
- 49. Lejon V, Mumba Ngoyi D, Kestens L, Boel L, Barbé B, Kande Betu V, et al. Gambiense Human
 African Trypanosomiasis and Immunological Memory: Effect on Phenotypic Lymphocyte Profiles
 and Humoral Immunity. PLoS Pathogens. 2014;10. doi:10.1371/journal.ppat.1003947
- 589 50. Pérez-Mazliah D, Ng DHL, Rosário APF do, McLaughlin S, Mastelic-Gavillet B, Sodenkamp J, et al.
 590 Disruption of IL-21 Signaling Affects T Cell-B Cell Interactions and Abrogates Protective Humoral
 591 Immunity to Malaria. PLOS Pathogens. 2015;11: e1004715. doi:10.1371/journal.ppat.1004715
- 592 51. Leonard WJ, Wan CK. IL-21 Signaling in Immunity. F1000Research. 2016;5.
 593 doi:10.12688/F1000RESEARCH.7634.1
- 52. de Leur K, Dor FJMF, Dieterich M, van der Laan LJW, Hendriks RW, Baan CC. IL-21 receptor
 antagonist inhibits differentiation of B cells toward plasmablasts upon alloantigen stimulation.
 Frontiers in Immunology. 2017;8: 306. doi:10.3389/FIMMU.2017.00306/FULL
- 53. Erman B, Bilic I, Hirschmugl T, Salzer E, Çagdas D, Esenboga S, et al. Combined immunodeficiency
 with CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation
 affecting IL21R. Haematologica. 2015;100: e216. doi:10.3324/HAEMATOL.2014.120980
- Kotlarz D, Ziętara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, et al. Loss-of-function
 mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. The Journal
 of Experimental Medicine. 2013;210: 433. doi:10.1084/JEM.20111229
- 55. Stepensky P, Keller B, Abuzaitoun O, Shaag A, Yaacov B, Unger S, et al. Extending the clinical and
 immunological phenotype of human interleukin-21 receptor deficiency. Haematologica.
 2015;100: e72. doi:10.3324/HAEMATOL.2014.112508

- 60656.Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nature607reviews Drug discovery. 2014;13: 379–395. doi:10.1038/NRD4296
- 57. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell
 costimulation, growth arrest, or Bim-dependent apoptosis. Journal of immunology (Baltimore,
 Md : 1950). 2004;173: 657–665. doi:10.4049/JIMMUNOL.173.1.657
- 58. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. IL-21 induces the apoptosis
 of resting and activated primary B cells. Journal of immunology (Baltimore, Md : 1950).
 2003;170: 4111–4118. doi:10.4049/JIMMUNOL.170.8.4111
- 59. Ozaki K, Spolski R, Ettinger R, Kim H-P, Wang G, Qi C-F, et al. Regulation of B cell differentiation
 and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. Journal of immunology
 (Baltimore, Md : 1950). 2004;173: 5361–5371. doi:10.4049/JIMMUNOL.173.9.5361
- 60. Bockstal V, Guirnalda P, Caljon G, Goenka R, Telfer JC, Frenkel D, et al. T. brucei infection reduces
 B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through
 transitional B-cell apoptosis. PLoS pathogens. 2011;7. doi:10.1371/JOURNAL.PPAT.1002089
- 61. Cnops J, Kauffmann F, De Trez C, Baltz T, Keirsse J, Radwanska M, et al. Maintenance of B cells
 during chronic murine Trypanosoma brucei gambiense infection. Parasite immunology. 2016;38:
 642–647. doi:10.1111/PIM.12344
- 62. M B, T O, A L, B H, P VDM, K K. Induction of interferon-gamma, transforming growth factor-beta,
 and interleukin-4 in mouse strains with different susceptibilities to Trypanosoma brucei brucei.
 Journal of interferon & cytokine research : the official journal of the International Society for
 626 Interferon and Cytokine Research. 1996;16: 427–433. doi:10.1089/JIR.1996.16.427
- 627 63. Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Ebeja AK, et al. The elimination of human
 628 African trypanosomiasis: Achievements in relation to WHO road map targets for 2020. PLoS
 629 neglected tropical diseases. 2022;16. doi:10.1371/JOURNAL.PNTD.0010047
- 630 64. Dickie EA, Giordani F, Gould MK, Mäser P, Burri C, Mottram JC, et al. New Drugs for Human
 631 African Trypanosomiasis: A Twenty First Century Success Story. Tropical medicine and infectious
 632 disease. 2020;5. doi:10.3390/TROPICALMED5010029
- 633 65. Koné M, Kaba D, Kaboré J, Thomas LF, Falzon LC, Koffi M, et al. Passive surveillance of human
 634 African trypanosomiasis in Côte d'Ivoire: Understanding prevalence, clinical symptoms and signs,
 635 and diagnostic test characteristics. PLoS neglected tropical diseases. 2021;15.
 636 doi:10.1371/JOURNAL.PNTD.0009656
- 66. "H3Africa Working Group on Ethics and Regulatory Issues for the Human Heredity and Health in
 Africa (H3Africa) Consortium." H3Africa Guideline for Informed Consent. 2013
- 639